CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤的风险适应性治疗：越多越好吗？
英文原题：Risk-adapted treatment in multiple myeloma: Does more make it merrier?
查看英文原题
Risk-adapted treatment in multiple myeloma: Does more make it merrier?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Kaiser等人针对适合移植的高危多发性骨髓瘤（HRMM）提出了管理建议，这些建议源自近期探索一线治疗各阶段治疗强化的试验。随着新型基因组学见解的出现和现代治疗的影响，HRMM的定义不断演变，强调需要超越传统的间期荧光原位杂交细胞遗传学和国际分期系统分期，以实现精确的风险评估。尽管取得了进展，治疗实施和耐受性方面的持续挑战凸显了探索T细胞重定向双特异性抗体和CAR-T 细胞等新方法的紧迫性，以改善这一复杂患者群体的结局。对以下文献的评论：Kaiser et al. Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper. Br J Haematol 2024; 205:833-839.
展开英文摘要原文
Kaiser et al. offer management recommendations for transplant-eligible, high-risk multiple myeloma (HRMM), derived from recent trials exploring treatment intensification in the various phases of front-line therapy. The definition of HRMM continues to evolve with emergence of novel genomic insights and impact of modern therapies, underscoring the need to expand beyond traditional interphase fluorescence in situ hybridization cytogenetics and International Staging System staging for a precise risk assessment.
Despite progress, ongoing challenges in treatment delivery and tolerability underscore the urgency for exploring novel approaches like T-cell redirecting bispecific antibodies and chimeric antigen receptor T-cell to enhance outcomes in this complex patient population. Commentary on: Kaiser et al. Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper. Br J Haematol 2024; 205:833-839.
论文信息
- 作者
- Zanwar S、Galarza Fortuna GM、Sborov DW
- 第一作者单位
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.United States
- 通讯作者单位
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.United States
- 期刊
- British journal of haematology2024 Sep
- 原文标识
- PubMed 39072706 · DOI 10.1111/bjh.19676